A randomized, single-blind, placebo-controlled, 4-way crossover phase I pharmacokinetic (PK) study of ORMD-0901
Phase of Trial: Phase I
Latest Information Update: 15 Jan 2019
At a glance
- Drugs Exenatide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Oramed Pharmaceuticals
- 15 Jan 2019 Status changed from planning to recruiting, according to an Oramed Pharmaceuticals media release.
- 15 Jan 2019 According to an Oramed Pharmaceuticals media release, this trial has been initited under an FDA IND and the company expects to complete this trial in 2019.
- 24 Sep 2018 New trial record